ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update

ADDISON, Texas, March 25 /PRNewswire-FirstCall/ -- ULURU Inc. today announced that it has scheduled a conference call to discuss the fourth quarter and year ended 2008 financial results and provide a general business update on Tuesday, March 31, 2009 at 10:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 9304#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on March 31, 2009 two hours following the end of the call until April 7, 2009 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 for international callers dial (585) 419-6446 (access code 9304#).

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and transmucosal delivery system. For more information about Altrazeal(TM), please visit http://www.altrazeal.com. For more information about ULURU Inc., please visit www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

CONTACT: Renaat E. Van den Hooff, President & CEO, or Terry K. Wallberg,
Vice President & CFO, both of ULURU Inc., +1-214-905-5145

Web site: http://www.uluruinc.com/

MORE ON THIS TOPIC